Literature DB >> 26526892

The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study.

V S Hegade1, M Krawczyk2,3, A E Kremer4, J Kuczka4, F Gaouar5, E M M Kuiper6, H R van Buuren6, F Lammert2, C Corpechot5, D E J Jones1.   

Abstract

BACKGROUND: Pruritus is a common symptom associated with cholestatic liver diseases. To date only small single centre case series have suggested efficacy of nasobiliary drainage in relieving cholestatic pruritus. AIM: To perform a multicentre study to evaluate the safety and efficacy of nasobiliary drainage in cholestatic pruritus.
METHODS: This was a retrospective study of all patients treated with nasobiliary drainage for refractory cholestatic pruritus between 2006 and 2015 at five European centres. Pruritus was quantified using a visual analogue scale (VAS) and liver enzymes, serum bilirubin and total serum bile salts (TBS) were measured before (pre-NBD) and after nasobiliary drainage (post-NBD). We analysed the duration of treatment response and associated complications.
RESULTS: In total, 27 patients (59% females) underwent 29 nasobiliary drainage procedures. The median duration of NBD was 7 days. NBD decreased pruritus in 89.6% of cases (VAS from 10.0 to 0.3, P < 0.0001). The median percentage decline in pruritus VAS was 94% and 33% of patients were free of pruritus within 24 h of starting drainage. The duration of treatment response was independent of duration of drainage (P = 0.12) and bile output. Significant improvements were seen in the median levels of serum alkaline phosphatase (P = 0.001) and serum bilirubin (P = 0.03) but not in serum TBS (P = 0.07). Mild post-endoscopic retrograde cholangiopancreatography pancreatitis (31%) was the most frequent complication.
CONCLUSIONS: Nasobiliary drainage is effective in relieving cholestatic pruritus in most patients and has favourable effect on biomarkers of cholestasis. Nasobiliary drainage may be associated with high risk of adverse events, especially pancreatitis. Prospective studies are needed to confirm our findings.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 26526892     DOI: 10.1111/apt.13449

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  15 in total

1.  Extracorporeal devices for treatment of refractory pruritus in cholestatic liver disease.

Authors:  Roger Williams
Journal:  Hepatol Int       Date:  2017-06-06       Impact factor: 6.047

2.  Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease.

Authors:  Wonngarm Kittanamongkolchai; Ziad M El-Zoghby; J Eileen Hay; Russell H Wiesner; Patrick S Kamath; Nicholas F LaRusso; Kymberly D Watt; Carl H Cramer; Nelson Leung
Journal:  Hepatol Int       Date:  2016-12-08       Impact factor: 6.047

3.  Cholestatic pruritus: Emerging mechanisms and therapeutics.

Authors:  Sagar P Patel; Chirag Vasavda; Byron Ho; James Meixiong; Xinzhong Dong; Shawn G Kwatra
Journal:  J Am Acad Dermatol       Date:  2019-04-19       Impact factor: 11.527

4.  MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus.

Authors:  James Meixiong; Chirag Vasavda; Solomon H Snyder; Xinzhong Dong
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-08       Impact factor: 11.205

Review 5.  Cholestatic Itch: Our Current Understanding of Pathophysiology and Treatments.

Authors:  Ashley Vander Does; Cynthia Levy; Gil Yosipovitch
Journal:  Am J Clin Dermatol       Date:  2022-07-28       Impact factor: 6.233

6.  Nasobiliary drainage: an effective treatment for pruritus in cholestatic liver disease.

Authors:  Wafaa Ahmed; Rebecca Jeyaraj; David Reffitt; John Devlin; Abid Suddle; John Hunt; Michael A Heneghan; Phillip Harrison; Deepak Joshi
Journal:  Frontline Gastroenterol       Date:  2022-01-11

7.  Nasobiliary drainage prior to surgical biliary diversion in progressive familial intrahepatic cholestasis type II.

Authors:  Giulia Jannone; Xavier Stephenne; Isabelle Scheers; Françoise Smets; Catherine de Magnée; Raymond Reding; Etienne M Sokal
Journal:  Eur J Pediatr       Date:  2020-04-14       Impact factor: 3.183

Review 8.  Novel strategies and therapeutic options for the management of primary biliary cholangitis.

Authors:  Amardeep Khanna; David E Jones
Journal:  Therap Adv Gastroenterol       Date:  2017-09-07       Impact factor: 4.409

9.  Can genetic testing guide the therapy of cholestatic pruritus? A case of benign recurrent intrahepatic cholestasis type 2 with severe nasobiliary drainage-refractory itch.

Authors:  Robert Holz; Andreas E Kremer; Dieter Lütjohann; Hermann E Wasmuth; Frank Lammert; Marcin Krawczyk
Journal:  Hepatol Commun       Date:  2018-01-10

10.  BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.

Authors:  Vinod S Hegade; Stuart F W Kendrick; Robert L Dobbins; Sam R Miller; Duncan Richards; James Storey; George Dukes; Kim Gilchrist; Susan Vallow; Graeme J Alexander; Margaret Corrigan; Gideon M Hirschfield; David E J Jones
Journal:  BMC Gastroenterol       Date:  2016-07-19       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.